Search

Start typing to see results...

  • Home
  • >
  • Stock Market
  • >
  • Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd share price and stock overview

Glenmark Pharmaceuticals Ltd (NSE: GLENMARK, BSE: 532296) operates in the Pharmaceuticals - Indian - Bulk Drugs & Formln sector. The stock has an ISIN of INE935A01035 and a face value of Rs 1. As of 13 September 2026, it trades at Rs (2,419.20) with a market capitalisation of Rs 68210.88 crore. Figures are live and subject to change.

Glenmark Pharmaceuticals Ltd

Pharmaceuticals - Indian - Bulk Drugs & Formln
NSE BSE
2,419.20 4.20 (0.17%) upARrowC
As on: 13-Sep-2026 , 03:30 AM
Market Cap(₹Cr) 68210.88
Book Value(₹Cr) 855.7128074
BSE Code : 532296 NSE Symbol : GLENMARK EPS(TTM) : 51.73 ISIN Demat : INE935A01035 P/E(TTM) : 46.72 Face Value(₹) : 1 Div & Yield % : 0.21

Today Market

Stock Performance

Today Market

Today's High

74,917.15

Todday's Low

74,160.16

Open at

74,309.16

Previous Close

74,902.59

Volumes

Avg Price

-120.83

Historical Performance

News

11 Sep 26
India Ratings affirmed Glenmark Pharmaceuticals' Bank Loans with an IND AA+ stable outlook
Glenmark Pharmaceuticals Ltd announced credit rating actions from India Ratings and Research, which affirmed its IND AA+ rating with a stable outlook for its Bank Loans and also rated Additional Loans, though specific details regarding the Additional Loans rating were not provided.
26 Aug 26
Glenmark Pharmaceuticals Ltd spurts 1.8%, up for third straight session
Glenmark Pharmaceuticals Ltd rose for a third straight session today. The stock is quoting at Rs 2443.
10 Aug 26
Glenmark Pharmaceuticals allotted equity shares under ESOP 2016, raising paid-up capital
Glenmark Pharmaceuticals Limited announced the allotment of 23,863 equity shares on August 10, 2026, under its Employee Stock Option Plan 2016 (ESOP 2016), increasing the company's paid-up capital from Rs 28,22,00,809 to Rs 28,22,24,672 and the total number of equity shares from 28,22,00,809 to 28,22,24,672.
31 Jul 26
Immunogenics advances multispecific therapeutics with AbbVie, Glenmark collaborations, potential $1.225 billion
Immunogenics, Inc. continues to advance its pipeline of multispecific therapeutics, highlighted by the Phase 1 dose expansion trial for ISB 2001/ABBV-2001, a trispecific antibody for multiple myeloma, currently underway in Australia, the US, and Europe.

Historical Prices

Share Price Chart

Historical Share Price

From Date:
To Date:     
Date Open Price (₹) High Price(₹) Low Price(₹) Close Price(₹) Total Volume No of Trades Net Turnover(₹) NIFTY
11-09-26 2411.20 2431.90 2384.10 2419.20 346692 34939 837167783.50 23398.10
10-09-26 2445.90 2449.90 2403.10 2415.00 262107 25792 634889477.20 23477.80
09-09-26 2486.90 2486.90 2400.10 2435.00 424753 34891 1032144201.10 23431.50
08-09-26 2469.90 2492.00 2439.00 2474.50 447432 46952 1105826494.50 23635.10
07-09-26 2420.20 2472.00 2420.20 2451.90 267568 29294 656889629.70 23779.15
04-09-26 2454.50 2456.70 2422.70 2437.20 412728 25342 1005401462.60 23897.70
03-09-26 2470.00 2471.80 2425.10 2459.00 481343 34285 1173404986.60 23873.45
02-09-26 2455.00 2476.90 2420.00 2460.00 516029 26799 1262181585.60 23914.45
01-09-26 2480.00 2494.90 2455.00 2470.40 679565 33397 1680882218.10 24055.80
31-08-26 2532.40 2532.40 2452.00 2480.00 911026 39619 2259229272.10 24080.40
123...

Fundamentals

Company Valuation

Market Cap (₹cr)

68210.88

PE Ratio

46.72

PB Ratio

2.82

Dividend Yield

0.21

ROE

3.87

ROCE

6.30

Book Value (₹)

855.7128074

Face Value (₹)

1

Share Holding Pattern

Category of Shareholder No of Shares % Share Holdings Demat Shares Share Holders
plus  Promoter & Group
plus  Foreign
Foreign (Promoter & Group) - Bodies Corporate 0 0.00 0 0
Foreign (Promoter & Group)-Individuals (Non-Resident / Foreign) 0 0.00 0 0
Foreign Promoter(Institutional) 0 0.00 0 0
Promoter Others 0 0.00 0 0
Sub Total 0 0.00 0 0
plus  Indian
Bodies Corporate-Indian (Promoter & Group) 0 0.00 0 0
Government(Central / State)-Indian (Promoter & Group) 0 0.00 0 0
Directors & their Relatives-Indian (Promoter & Group) 0 0.00 0 0
Financial Institutions / Banks-Indian (Promoter & Group) 0 0.00 0 0
Individuals / Hindu Undivided Family-Indian (Promoter & Group) 3415386 1.21 3415386 5
Partnership Firms-Indian (Promoter & Group) 0 0.00 0 0
Persons Acting in Concert 0 0.00 0 0
Trusts 128241936 45.44 128241936 1
Others 0 0.00 0 0
Sub Total 131657322 46.65 131657322 6
Total ShareHolding for Promoter & Group 131657322 46.65 131657322 6
plus   Publice Share Holding
plus  Institution
Government(Central / State) 107037 0.04 107037 3
Clearing Members 0 0.00 0 0
Corporate Bodies 0 0.00 0 0
Foreign Direct Investments 0 0.00 0 0
Financial Institutions / Banks 290043 0.10 290043 3
Foreign Bank 0 0.00 0 0
Foreign Bodies Corporate/OCBs/FBC 0 0.00 0 0
Foreign Collaborators 0 0.00 0 0
Foreign Institutional Investors 58959712 20.89 58959712 376
Foreign Venture Capital Investors 0 0.00 0 0
Foreign Institution Other 0 0.00 0 0
Insurance Companies 2866650 1.02 2866650 18
Mutual Funds / UTI 47294735 16.76 47294735 37
Individuals (Non-Resident / Foreign) 0 0.00 0 0
NSDL Intransit 0 0.00 0 0
Others 2050205 0.73 2050205 36
Trusts 0 0.00 0 0
Venture Capital Funds 0 0.00 0 0
Sub total 111568382 39.54 111568382 473
plus  Non Institution
Bodies Corporate 5857675 2.08 5857675 1330
Clearing Members 637 0.00 637 5
Directors & their Relatives 35 0.00 35 1
Employees 0 0.00 0 0
Escrow Account 0 0.00 0 0
Foreign Corporate Bodies 0 0.00 0 0
Foreign Direct Investments 0 0.00 0 0
NRIs/Foreign Individuals/Foreign Nationals 2319787 0.82 2315787 6325
Foreign Non Institution Other 0 0.00 0 0
Hindu Undivided Families 541779 0.19 541779 3551
Indian Public 0 0.00 0 0
Individuals holding nominal share capital in excess of Rs. 1 lakh 7595046 2.69 6995046 14
Individuals holding nominal share capital up to Rs. 1 lakh 22308732 7.91 22101398 199701
Market Maker 0 0.00 0 0
NSDL Transit 0 0.00 0 0
Shares in transit 0 0.00 0 0
Societies 0 0.00 0 0
Trust & Foundation 64236 0.02 64236 9
Others 287178 0.10 287178 3
Sub Total 38975105 13.81 38163771 210939
Total Public Shareholding 150543487 53.35 149732153 211412
Total of Promoter & Public ShareHolding 282200809 100.00 281389475 211418
plus  Shares held by Custodians and against which Depository Receipts have been issued
ADR 0 0.00 0 0
GDR 0 0.00 0 0
Other Custodians 0 0.00 0 0
Total Shares held by Custodians and against which Depository Receipts have been issued 0 0.00 0 0
Grand Total 282200809 100.00 281389475 211418

Financials (₹ in cr)

Consolidated Standalone
Year EndMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Net Sales16,982.5113,321.7411,813.1011,583.2412,304.90
OPM (%)25.0313.307.948.6813.83
OP4,250.831,772.03937.451,005.701,702.16
Other Income460.62113.72839.99288.90166.67
PBIDT2,766.952,092.281,134.371,158.052,226.06
INTEREST208.73207.07515.97349.04298.10
PBDT2,558.231,885.22618.40809.021,927.96
PBT-281.341,026.39-864.46-526.011,180.33
EO-2,266.08-372.82-900.96-765.85-260.91
PBT after EO1,984.751,399.2136.50239.841,441.25
TAXES622.79352.071,867.35329.40447.60
PAT1,361.851,047.10-1,501.67297.25941.71
EPS48.2437.11-53.2210.5333.37
Raw Material17.4422.5326.7327.5026.65
Power and Fuel0.610.780.790.751.47
Employee Cost21.0722.6924.2822.4519.89
Other Manufacturing Expenses0.860.671.060.600.60
Selling and Administration Expenses13.4914.8214.4115.1312.54
Miscellaneous Expenses5.635.916.425.575.66
Revenue (Growth %) 27.4812.771.98-5.8612.44
PBIDT (Growth %)32.2584.44-2.04-47.982.15
PAT (Growth %) 30.06-169.73-605.20-68.44-2.92
PBIDT (Margin %)16.2915.719.6010.0018.09
PAT (Margin %) 8.027.86-12.712.577.65

Balance Sheet (₹ in cr)

Particulars (Sources Of Funds)Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Share Capital 28.2228.2228.2228.2228.2228.22
Reserves Total 24122.1024475.7422942.4017849.2516710.3714781.29
Equity Share Warrants0.000.000.000.000.000.00
Equity Application Money0.000.000.000.000.000.00
Total Shareholders Funds24150.3224503.9622970.6217877.4716738.5914809.51
Secured Loans 0.00298.820.000.000.000.00
Unsecured Loans 107.01530.97707.293221.223737.703703.99
Total Debt107.01829.79707.293221.223737.703703.99
Other Liabilities1591.09132.10131.94372.58121.32136.61
Total Liabilities25848.4225465.8523809.8521471.2720597.6118650.11
APPLICATION OF FUNDS :
Gross Block 4015.833743.153392.753183.653026.282848.56
Less : Accumulated Depreciation 1987.931763.971636.501437.701273.951126.07
Less:Impairment of Assets0.000.000.000.000.000.00
Net Block 2027.901979.181756.251745.951752.331722.49
Lease Adjustment0.000.000.000.000.000.00
Capital Work in Progress159.32154.56197.67172.34109.04131.40
Producing Properties0.000.000.000.000.000.00
Investments 15202.2115194.9112964.7910334.018559.396989.95
Current Assets, Loans & Advances
Inventories 1288.061369.311142.691090.21951.66762.39
Sundry Debtors 3305.592550.162484.472505.662678.322488.75
Cash and Bank Balance293.19132.74129.1593.7929.6315.79
Loans and Advances 1208.26725.47925.17695.51743.311642.20
Total Current Assets6095.104777.684681.484385.184402.934909.12
Less : Current Liabilities and Provisions
Current Liabilities 3270.502383.393249.792952.142168.391834.31
Provisions 366.26125.79354.74162.52148.49133.11
Total Current Liabilities & Provisions3636.762509.183604.543114.662316.881967.41
Net Current Assets2458.342268.501076.941270.522086.052941.71
Miscellaneous Expenses not written off 0.000.000.000.000.000.00
Deferred Tax Assets968.61166.59475.611160.251137.471118.72
Deferred Tax Liability962.57224.85309.77213.50214.20265.43
Net Deferred Tax6.04-58.26165.84946.75923.27853.29
Other Assets5994.615926.977648.377001.707167.546011.27
Total Assets25848.4225465.8623809.8521471.2620597.6218650.11
Contingent Liabilities2590.042949.432658.493443.303325.063730.17

Cash Flow (₹ in cr)

Yearly Cash FlowMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Financing Activities -305.12-978.50-2,666.45-95.41-952.13
Investing Activities -897.02-431.523,197.17-489.90569.21
Net Cash Flow 13.9364.0535.273.49160.38
Operating Activities 1,216.071,474.06-495.45588.80543.30

Corporate Actions

Bonus Dividends Splits
DateCorporate ActionInformation
No Corporate Actions Announced

Board of Directors

Chairman & Chief Executive Officer
GS
Glenn Saldanha
Chairman / Executive Director / M D / Promoter
Executive
Functional Directors
CP
Cheryl Pinto
Executive Director (Corporate)
Exec.
AM
Anurag Mantri
Executive Director & Group CFO
Exec.
BES
B E Saldanha
Non Executive Director
Exec.
Independent Directors
SSR
Sona Saira Ramasastry
Independent Non Exe. Director
Ind.
DB
Dipankar Bhattacharjee
Independent Non Exe. Director
Ind.
VRI
V R Iyer
Independent Non Exe. Director
Ind.
PKS
Pradeep Kumar Sinha
Independent Non Exe. Director
Ind.
PA
Patricia Andrews
Independent Non Exe. Director
Ind.
Company Secretary & Compliance
RK
Rashmi Khandelwal.
Company Secretary / Compliance Officer
Sec.

Frequently Asked Questions

What is the NSE symbol and BSE code for Glenmark Pharmaceuticals Ltd? −

Glenmark Pharmaceuticals Ltd trades on NSE under GLENMARK and on BSE under code 532296. The ISIN is INE935A01035 and the face value is Rs 1.

What is the share price of Glenmark Pharmaceuticals Ltd today? +

As of 13 September 2026, Glenmark Pharmaceuticals Ltd trades at Rs 2,419.20, a change of 4.20 (0.17%) on the day. Prices are live and subject to change.

What is the market capitalisation of Glenmark Pharmaceuticals Ltd? +

As of 13 September 2026, Glenmark Pharmaceuticals Ltd has a market cap of about Rs 68210.88 crore. This figure is live and moves with the share price.

Is Glenmark Pharmaceuticals Ltd profitable? +

In March 2026, Glenmark Pharmaceuticals Ltd reported a profit after tax of Rs 1,361.85 crore. The wording switches to "a net loss of Rs X crore" when the figure is negative.

What is the PE ratio of Glenmark Pharmaceuticals Ltd? +

: As of 13 September 2026, the PE (TTM) for Glenmark Pharmaceuticals Ltd is 46.72 and the price-to-book ratio is 2.82. When the PE shows zero, state that PE TTM is currently not applicable and give the PB only.

Does Glenmark Pharmaceuticals Ltd pay a dividend? +

As of 13 September 2026, the dividend yield for Glenmark Pharmaceuticals Ltd is 0.21%. The wording switches to "does not currently pay a dividend" when the yield is zero.

What is the shareholding pattern of Glenmark Pharmaceuticals Ltd? +

As of the latest disclosed pattern, promoters hold 46.65% of Glenmark Pharmaceuticals Ltd. Public shareholding is 53.35%, including mutual funds at 16.76% and foreign institutional investors at 20.89%.

What were the latest annual financials of Glenmark Pharmaceuticals Ltd? +

In March 2026, Glenmark Pharmaceuticals Ltd reported net sales of Rs 16,982.51 crore, revenue growth of 27.48%, and earnings per share of Rs 48.24.